In a recent study published in JAMA, researchers investigated whether Tongxinluo, a Chinese medicinal compound, could improve clinical outcomes among ST-segment elevation myocardial infarction (STEMI) ...

A bivalent messenger RNA vaccine targeting both the ancestral and omicron BA.4–BA.5 sublineages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Pfizer–BioNTech) was introduced in ...

Myocardial infarction (MI) and stroke are the most common acute life-threatening cardiovascular disease (CVD) events and are triggered by the rupture of lipid-rich plaques in the arterial wall during ...

About The Study: In this randomized clinical trial of 3,777 patients with ST-segment elevation myocardial infarction (STEMI; a type of heart attack), the Chinese patent medicine Tongxinluo, as an ...

Dr. Patrick Malecha (Medicine): A 69-year-old man with a history of myocardial infarction, ischemic cardiomyopathy, and an implantable cardioverter–defibrillator (ICD) was evaluated because of dyspnea ...